Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2576)

(1) PROPOSED RE-ELECTION AND ELECTION OF DIRECTORS OF THE THIRD SESSION OF THE BOARD; AND (2) PROPOSED RE-ELECTION OF SHAREHOLDERS' REPRESENTATIVE SUPERVISORS OF THE THIRD SESSION OF THE SUPERVISORY COMMITTEE

1. PROPOSED RE-ELECTION AND ELECTION OF DIRECTORS OF THE THIRD SESSION OF THE BOARD

The board (the "**Board**") of directors (the "**Directors**") of Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that pursuant to Article 95 of the articles of association of the Company (the "**Articles of Association**"), Directors shall be elected or replaced at the general meeting and may be removed by the general meeting before the expiration of their term of office. A Director shall serve a term of three years and can be re-elected upon the expiry of the tenure.

The original term of office of the second session of the Board will expire on 21 September 2026. Pursuant to the Articles of Association, the Board is pleased to announce that the Company has completed the procedures for nomination of Director candidates for the third session of the Board, and on June 1, 2026, the Board resolved to:

(i) nominate Dr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming and Ms. NI Xiaomei to be re-elected as executive Directors;

(ii) nominate Ms. WAN Yunyun to be elected as an executive Director;

(iii) nominate Dr. JIANG Xiao and Mr. FUNG Che Wai Anthony to be re-elected as independent non-executive Directors; and

(iv) nominate Dr. GONG Yan to be elected as an independent non-executive Director.

(each as a "**Candidate Director**", and collectively as the "**Candidate Directors**")

The biographical details of the Candidate Directors are set out in Appendix I to this announcement.

The above proposals for re-election and election were put forth by the nomination committee of the Company (the "**Nomination Committee**") according to the Board diversity policy and nomination policy adopted by the Company taking into consideration the requirements of the Company. The Nomination Committee submitted such proposals to the Board for consideration after reviewing the relevant experience, skills and expertise of the Candidate Directors, which will be submitted by the Board at the general meeting of the Company for approval.

The ordinary resolutions regarding the aforesaid re-election and election of Candidate Directors will be proposed at the forthcoming annual general meeting of the Company (the "**AGM**") for consideration by the shareholders of the Company (the "**Shareholders**"). Subject to approval by the Shareholders at the AGM, each candidate Director shall serve a term of three years, commencing from the date of approval at the AGM, and shall be eligible for re-election upon expiry of the term.

Mr. HUANG Yufei (黄玉飛), the current executive Director of the second session of the Board, and Dr. LI Zhiguo (李治國), the current independent non-executive Director of the second session of the Board, will not stand for re-election as Directors of the third session of the Board at the AGM, and will cease to be Directors upon the election of the third session of the Board at the AGM. Dr. LI Zhiguo will also cease to be the chairman of the remuneration and appraisal committee of the Company, and a member of each of the audit committee and the Nomination Committee of the Company. They have confirmed to the Company that there is no disagreement between them and the Board, nor are there any matters in connection with their departure that need to be brought to the attention of the Shareholders.

The Board would like to express its sincere gratitude to Mr. HUANG Yufei and Dr. LI Zhiguo for their contributions to the Company during their respective terms of office.

2. PROPOSED RE-ELECTION OF SHAREHOLDERS' REPRESENTATIVE SUPERVISORS OF THE THIRD SESSION OF THE SUPERVISORY COMMITTEE

Pursuant to Article 137 of the Articles of Association, each supervisor (the "**Supervisor(s)**") of the supervisory committee of the Company (the "**Supervisory Committee**") shall serve a term of three years. Upon expiration of their term, Supervisors may serve consecutive terms if re-elected. Pursuant to Article 143 of the Articles of Association, the Supervisory Committee consists of three Supervisors. The

Supervisory Committee includes one employee representative supervisor. Shareholders' representatives of the Supervisory Committee shall be elected and removed by the general meeting, and employee representatives shall be democratically elected and removed by the employees of the Company through the employee representative' meeting, employees' general meeting or other forms.

The original term of office of the Supervisors of the second session of the Supervisory Committee will expire on September 21, 2026. In accordance with the Articles of Association, the Supervisory Committee resolved on June 1, 2026 to nominate Mr. WEN Gang and Mr. CAI Xin for re-election as Shareholders' representative Supervisors (each a "**Candidate Supervisor**", and collectively as the "**Candidate Supervisors**").

The biographical details of the Candidate Supervisors are set out in Appendix II to this announcement.

An ordinary resolution regarding the above-mentioned re-election of the Candidate Supervisors will be proposed at the AGM for consideration by the Shareholders. Subject to approval by the Shareholders at the AGM, each Candidate Supervisor shall serve a term of three years, commencing from the date of approval at the AGM, and shall be eligible for re-election upon expiry of the term.

The Shareholders' representative Supervisors to be elected at the AGM and the employee representative Supervisor to be democratically elected by the employees of the Company shall together comprise the third session of the Supervisory Committee. The employee representative Supervisor of the third session of the Supervisory Committee will be democratically elected by the employees of the Company, and the Company will make a separate announcement in due course.

CIRCULAR

A circular containing further details regarding the Candidate Directors and Candidate Supervisors nominated for election or re-election, together with the notice of the AGM, will be published and despatched by the Company to the Shareholders in due course in accordance with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Articles of Association.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Dr. ZHAO Lu
Chairman of the Board

Hong Kong, June 1, 2026

As at the date of this announcement, the Board comprises Dr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.

The biographical details of each Candidate Director are as follows:

Proposed Executive Directors

Dr. ZHAO Lu (趙璐) ("Dr. ZHAO")

Dr. ZHAO Lu, aged 47, is the chairman of our Board and an executive Director. Dr. ZHAO joined our Group since January 2016 as the general manager and has served as a Director since December 2016. He was re-designated as an executive Director on September 21, 2023. Due to work re-arrangement, Dr. ZHAO ceased to be our general manager with effect from February 11, 2025, details of which are set out in the announcement of the Company dated February 11, 2025. Dr. ZHAO is also currently an executive director of Shanghai Taimei Xingyun Digital Technology Co., Ltd. (上海太美星雲數字科技有限公司), an executive director of Shanghai Taimei Xinghuan Digital Technology Co., Ltd. (上海太美星環數字科技有限公司), an executive director of Taimei Zhiyan Pharmaceutical R&D (Shanghai) Co., Ltd. (太美智研醫藥研發(上海)有限公司) ("**Taimei Zhiyan**"), an executive director of Hangzhou Taimei Xingcheng Pharmaceutical Technology Co., Ltd. (杭州太美星程醫藥科技有限公司) and an executive director and the general manager of Shanghai Taimei Xinghui Enterprise Management Co., Ltd. (上海太美星輝企業管理有限公司). He is primarily responsible for strategic planning, execution, operation and overall management of our Group.

Dr. ZHAO has more than 24 years of experience in the pharmaceutical and medical science industries. Prior to joining our Group, from August 2000 to March 2001, he was a technician and sales representative at Shanghai Sine Pharmaceuticals Co., Ltd. (上海信誼藥業有限公司), a pharmaceutical manufacturer, where he was primarily responsible for pharmaceutical sales. From March 2001 to April 2008, he was a product manager at the oncology and biotechnology products department at Schering-Plough (China) Co., Ltd. (先靈葆雅(中國)有限公司) (a subsidiary of Merck & Co., Inc. (formerly known as Schering-Plough Corporation) which is a multinational pharmaceutical company listed on the New York Stock Exchange (stock symbol: MRK)) in the PRC, where he was primarily responsible for pharmaceutical marketing. Besides, Dr. ZHAO was a co-founder of Shanghai Jsure Health Technology Co., Ltd. (上海捷信醫藥科技股份有限公司) (a digital patient solution provider in the pharmaceutical industry), and served as its director from June 2008 to January 2017 and deputy general manager from June 2008 to January 2016, where he was primarily responsible for formulation of business development strategies and market expansion.

Dr. ZHAO obtained his bachelor's degree in biotechnology and pharmacy jointly from Shenyang Pharmaceutical University (瀋陽藥科大學) in Liaoning and Jilin University (吉林大學) in Jilin in July 2000. He further obtained his executive master of business administration degree jointly from Fudan University (復旦大學) in Shanghai and National Taiwan University (國立台灣大學) in Taiwan, China in January 2019. In March 2026, Dr. ZHAO was conferred the degree of doctor of business administration by China Europe International Business School (Switzerland) (中歐國際工商學院(瑞士)).

Mr. MA Dong (馬東) ("Mr. MA")

Mr. MA Dong, aged 43, is an executive Director and the chief product officer of our Company. He joined our Group as the president of the digital R&D division in December 2014, and has been the chief product officer since February 2024. Since February 2025, he has acted as head of overseas business division of our Group. Mr. MA has further served as a Director since July 2017, and was re-designated as an executive Director on September 21, 2023. He is also currently an executive director and the general manager of Shanghai Taimei International Consulting Co., Ltd. (上海太美星際企業諮詢有限公司). He is primarily responsible for management and operation of overseas business department of our Group.

Mr. MA has more than 11 years of experience in clinical research and medical editorials. Prior to joining our Group, from August 2009 to August 2010, he was a project assistant at Shanghai Hengrui Pharmaceuticals Co., Ltd. (上海恒瑞醫藥有限公司), a company principally engaged in pharmaceutical R&D and a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600276)), where he was primarily responsible for formulation of clinical research protocols and project management. From November 2012 to May 2014, he was a clinical supervising associate at Parexel China Co., Ltd. (精鼎醫藥研究開發(上海)有限公司), a contract research organization, where he was primarily responsible for supervising clinical research. From May 2014 to December 2014, Mr. MA worked at WuXi Clinical Development Services (Shanghai) Co., Ltd. (上海康德弘翼醫學臨床研究有限公司) (formerly known as Shanghai Kangde Baorui Clinical Development Co., Ltd. (上海康德保瑞醫學臨床研究有限公司)), a contract research organization and a wholly-owned subsidiary of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (a company listed on the Stock Exchange (stock code: 2359)), where he was primarily responsible for designing clinical research protocols. He also previously worked at Shanghai THINK Advertising Co., Ltd. (上海欣可廣告有限公司) (a marketing service provider).

Mr. MA obtained his bachelor's degree in basic medicine from Fudan University (復旦大學) in Shanghai in July 2006. He further obtained his master's degree in pharmacology from Shanghai Institute of Pharmaceutical Industry (上海醫藥工業研究院) in Shanghai in June 2009 and his master's degree in business administration from the University of Hong Kong in Hong Kong in December 2020.

Mr. ZHANG Hongwei (張宏偉) ("Mr. ZHANG")

Mr. ZHANG Hongwei, aged 46, is an executive Director and the head of the digital marketing division of our Company. He joined our Group as the head of the digital marketing division since January 2015, and has served as strategic vice president of Taimei Zhiyan since October 2025. Mr. ZHANG has further served as a Director since February 2016, and was re-designated as an executive Director on September 21, 2023. He is primarily responsible for participating in the formulation and planning of the strategic development direction of Taimei Zhiyan, and empowering its business upgrading and value enhancement.

Mr. ZHANG has more than 11 years of experience in the pharmaceutical and medical industries. Prior to joining our Group, from September 2001 to December 2004, he was successively the head of the general manager's office at Shanghai Sine Pharmaceutical Equipment Co., Ltd. (上海信誼製藥裝備有限公司) (a pharmaceutical equipment manufacturer), an assistant to the general manager at Shanxi Xinyitong Pharmaceutical Co., Ltd. (山西信誼通製藥有限公司) (a company principally engaged in manufacturing and sales of pharmaceuticals and medical devices) and a deputy general manager at Shanghai Sine Pharmaceutical Equipment Co., Ltd.. From August 2010 to August 2012, he was a strategic development manager at Sanofi (China) Investment Co., Ltd. (賽諾菲(中國)投資有限公司), an investment management company. From September 2012 to February 2013, he was a manager at LEO Pharma Consultancy (Shanghai) Company Limited (上海勵奧醫藥諮詢有限公司), a company principally engaged in provision of medical consultancy services. From June 2013 to February 2014, Mr. ZHANG was a national manager of the patient support division at Bristol Myers Squibb (Shanghai) Trading Co., Ltd. (百時美施貴寶(上海)貿易有限公司), a company principally engaged in marketing and sales of pharmaceuticals, nutritional products and medical devices. From March 2014 to January 2015, he was a national manager of the patient management division at AstraZeneca Investment (China) Co., Ltd. (阿斯利康投資(中國)有限公司), a pharmaceutical company, where he was primarily responsible for patient management.

Mr. ZHANG obtained his college degree in pharmaceutical equipment from Shanghai University of Medicine & Health Sciences (上海健康醫學院) (formerly known as Shanghai Medical Equipment College (上海醫療器械高等專科學校)) in Shanghai in July 2001. He further obtained his master's degree in business administration from Fudan University (復旦大學) in Shanghai in January 2012.

Mr. LU Yiming (陸一鳴) ("Mr. LU")

Mr. LU Yiming, aged 44, is an executive Director and the chief technology officer of our Company. He joined our Group as the president of the R&D division in May 2018, and has been the chief technology officer since March 2024. Between January 2021 and March 2024, he was a Shareholders' representative Supervisor. Mr. LU was appointed as an executive Director on March 27, 2024. He is primarily responsible for management and operation of the R&D division of our Group.

Mr. LU has more than 15 years of experience in information technology and software engineering. Prior to joining our Group, from October 2008 to August 2011, he was a senior engineer at Microsoft Inc., a company listed on Nasdaq (stock symbol: MSFT), where he was primarily responsible for designs and R&D of the operating system of the company. From August 2011 to August 2015, he was a senior architect at Box Inc., a company listed on the New York Stock Exchange (stock symbol: BOX), where he was primarily responsible for R&D and system architecture of cloud services for file collaboration. Further, from September 2015 to April 2018, Mr. LU was a vice president of technology at Beijing Xieli Zhucheng Technology Information Services Co., Ltd. (北京協力築成科技資訊服務股份有限公司) (formerly known as Beijing Xieli Zhucheng Financial Information Service Co., Ltd. (北京協力築成金融資訊服務有限公司)), a company principally engaged in provision of media consultancy, corporate, financial information and venture capital services, where he was primarily responsible for the R&D and management of the company's media platform and venture financing platform. Mr. LU obtained his bachelor's degree in computer science and technology from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 2003. He further obtained his master's degree in computer system structure from Shanghai Jiao Tong University (上海交通大學) in Shanghai and his master's degree in information and computer science from the University of California, Irvine in California in March 2006 and September 2008, respectively. Mr. LU is currently doing an executive master of business administration program at China Europe International Business School (中歐國際工商學院) in Shanghai.

Ms. NI Xiaomei (倪曉梅) ("Ms. NI")

Ms. NI Xiaomei, aged 55, is an executive Director, the legal director, the Board secretary and the joint company secretaries. She joined our Group as a deputy general manager, the legal director and the Board secretary in April 2018, and has been the legal director and the Board secretary since then. Ms. NI has further served as a Director since June 2018, and was re-designated as an executive Director on September 21, 2023. Ms. NI has been appointed as the joint company secretaries of the Company since July 31, 2023. Ms. NI is primarily responsible for securities-related and legal affairs of our Group and providing support to our Board.

Ms. NI has more than 18 years of experience in legal related matters. From March 2007 to April 2018, Ms. NI was a lawyer at Shanghai GF Law Firm (上海市廣發律師事務所), where she was primarily responsible for providing legal services on securities-related, financing and corporate matters.

Ms. NI obtained her bachelor's degree in industrial design from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 1992. She further obtained her master's degree in civil and commercial laws from East China University of Political Science and Law (華東政法大學) in Shanghai in December 2007. Ms. NI obtained her qualification of legal profession from the Ministry of Justice of the PRC (中華人民共和國司法部) in February 2007.

Ms. WAN Yunyun (萬韞鋆) ("Ms. WAN")

Ms. WAN Yunyun, aged 41, was appointed as our general manager on February 11, 2025. Ms. WAN joined the Group in February 2016 as a vice president of the business development division of the Company. From October 2019 to June 2023, Ms. WAN was the president of the business-to-business division of the Company. Since June 2023, she has been the president of the digital services division, a senior vice president and the chief commercial officer of the Company. Ms. WAN is also currently the general manager of a subsidiary of the Company, Shanghai Taimei Xingyun Digital Technology Co., Ltd. (上海太美星雲數字科技有限公司). She is primarily responsible for management and operation of the digital services division of the Group.

Ms. WAN has more than 16 years of experience in the pharmaceutical and medical science industries. Prior to joining the Group, from July 2005 to March 2006, she was an electronic engineer at Compal Electronics Technology (Kunshan) Co., Ltd. (仁寶電子科技(崑山)有限公司), a company principally engaged in manufacturing of electronic devices, where she was primarily responsible for providing assistance in research. From March 2006 to July 2009, she was a client manager at Shanghai Betterway Marketing Services Co., Ltd. (上海百達輝琪營銷服務有限公司), a company principally engaged in provision of advertising services, where she was primarily responsible for project management. From September 2009 to February 2016, she was a vice president of business development and a supervisor of Shanghai Jsure Health Technology Co., Ltd. (上海捷信醫藥科技股份有限公司), a digital patient solution provider in the pharmaceutical industry, where she was primarily responsible for sales of products to enterprises.

Ms. WAN graduated with a major in public relations from Fudan University (復旦大學) in Shanghai in January 2010. She obtained her master's degree in business administration from Fudan University in Shanghai in January 2020 and her master's degree in business administration from China Europe International Business School (中歐國際工商學院) in Shanghai in November 2023. Ms. WAN further obtained her executive master of business administration in hospitality jointly from China Europe International Business School in Shanghai and EHL Hospitality Business School in Switzerland in April 2024.

Proposed Independent Non-executive Directors

Dr. JIANG Xiao (蔣驍) ("Dr. JIANG")

Dr. JIANG Xiao, aged 48, joined our Group since September 2020 as an independent Director and was re-designated as an independent non-executive Director on September 21, 2023. He is primarily responsible for providing independent advice and judgment to our Board.

Dr. JIANG has over 22 years of experience in investment and asset appraisal industries. From February 2003 to July 2024, he worked at and last served as the president and a director of Shanghai Orient Appraisal Co., Ltd. (上海東洲資產評估有限公司) ("**Shanghai Orient**"), a company principally engaged in provision of business valuation and asset appraisal services. He was also a director of Zhoulan Valuation Technology Research (Wuxi) Co., Ltd. (洲瀾估值技術研究(無錫)有限公司) from February 2022 to November 2023 and a director of Zhoulan (Shanghai) Asset Appraisal Co., Ltd. (洲藍(上海)資產評估有限公司) from April 2022 to March 2024, both of which are subsidiaries of Shanghai Orient. From October 2005 to December 2019, he was an executive director of Shanghai Hui Zhi Enterprise Management Consulting Co., Ltd. (上海輝智企業管理諮詢有限公司), a management consultancy firm. From April 2016 to April 2022, Dr. JIANG was an independent director of Angel Yeast Co., Ltd. (安琪酵母股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600298). From December 2018 to December 2021, he was an independent director of Welltrans O&E Co., Ltd. (武漢微創光電股份有限公司), a company listed on the Beijing Stock Exchange (stock code: 430198). From November 2017 to June 2021, Dr. JIANG was an executive director of Shanghai BroadMesse International Creative & Technology Co., Ltd. (上海寬創國際文化科技股份有限公司), a company principally engaged in provision of design, fabrication, installation and technology solutions for exhibitions and events. From June 2020 to May 2026, he has been an independent director of Techstorm Advanced Material Corporation Limited (道生天合材料科技(上海)股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601026). From September 2022 to December 2025, he served as an independent director of Jinbei Automobile Co., Ltd. (金杯汽車股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600609). From February 2024 to October 2025, he served as an independent director of Tianfeng Securities Co., Ltd. (天風證券股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601162). From June 2021 to December 2022, he was an executive director of Shanghai Zhoulan Technology Co., Ltd. (上海洲瀾科技有限公司), a wholly-owned subsidiary of Shanghai Orient principally engaged in R&D and provision of enterprise consulting services with intelligent solutions. Since November 2022, Dr. JIANG has also been a director of Zhoulan Heyuan (Shanghai) Enterprise Service Co., Ltd. (洲藍郃願(上海)企業服務有限公司), an asset appraisal firm. Since July 2024, he has served as the chairman of the board of directors of Jinzheng (Shanghai) Asset Appraisal Co., Ltd. (金證(上海)資產評估有限公司), a company principally engaged in provision of business valuation and asset appraisal services, where he has been primarily responsible for overseeing the daily management and operation of the company. Besides, Dr. JIANG has been an independent director of Shanghai Friendess Electronic Technology Corporation Limited (上海柏楚電子科技股份有限公司), a company listed on the Shanghai Stock Exchange STAR Market (stock code: 688188), since June 2024.

Dr. JIANG obtained his bachelor's degree in economics and master's degree in economics from Soochow University (蘇州大學) in Jiangsu in June 2000 and July 2003, respectively. Dr. JIANG further obtained his doctor's degree in management from Business School Netherlands in the Netherlands in September 2016. Dr. JIANG obtained his qualification as an asset appraiser from the China Appraisal Society (中國資產評估協會) in June 2008.

Mr. FUNG Che Wai Anthony (馮志偉) ("Mr. FUNG")

Mr. FUNG Che Wai Anthony, aged 57, was appointed as an independent non-executive Director on September 21, 2023. He is primarily responsible for providing independent advice and judgment to our Board.

Mr. FUNG has more than 33 years of experience in the accounting, consulting services, investor relations and financial management. From August 1992 to September 1999, Mr. FUNG was an auditor at Deloitte Touche Tohmatsu, an accounting firm, where he was primarily responsible for providing audit services. From October 1999 to August 2007, he was a director of Winsmart Consultants Limited (弘陞投資顧問有限公司), a financial consulting firm, where he was primarily responsible for advising on pre-listing matters. From January 2008 to August 2010, he was a vice president of NagaCorp Ltd. (金界控股有限公司), a company listed on the Stock Exchange (stock code: 3918), where he was primarily responsible for investor relations matters. From January 2011 to July 2014, he was the chief financial officer and company secretary of Zall Smart Commerce Group Ltd. (卓爾智聯集團有限公司), a company listed on the Stock Exchange (stock code: 2098), where he was primarily responsible for financial management. From July 2014 to April 2017, Mr. FUNG served as the chief financial officer and company secretary of Kong Sun Holdings Limited (江山控股有限公司), a company listed on the Stock Exchange (stock code: 295), where he was primarily responsible for financial management. From May 2017 to December 2022, he was the chief financial officer and company secretary of Beijing Enterprises Urban Resources Group Limited (北控城市資源集團有限公司), a company listed on the Stock Exchange (stock code: 3718), where he was primarily responsible for financial management. Mr. FUNG also served as an independent non-executive director of FY Financial (Shenzhen) Co., Ltd. (富銀融資租賃(深圳)有限公司) (a company listed on the Stock Exchange (stock code: 8452)) from April 2017 to August 2023, and S&P International Holding Limited (椰豐集團有限公司) (a company listed on the Stock Exchange (stock code: 1695)) from June 2017 to October 2021, and Dekon Food and Agriculture Group (四川德康農牧食品集團股份有限公司) (a company listed on the Stock Exchange (stock code: 2419)) from October 2023 to February 2026, where he was primarily responsible for providing independent advice to the board of directors of the aforementioned companies.

Besides, Mr. FUNG has been an independent non-executive director of KWG Living Group Holdings Limited (合景悠活集團控股有限公司) (a company listed on the Stock Exchange (stock code: 3913)) since October 2020, Zhong An Group Limited (眾安集團有限公司) (a company listed on the Stock Exchange (stock code: 672)) since November 2021, XXF Group Holdings Limited (喜相逢集團控股有限公司) (a company listed on the Stock Exchange (stock code: 2473)) since October 2023, and Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司) (a company listed on the Stock Exchange (stock code: 2509)) since January 2024, where he has been primarily responsible for providing independent advice to the board of directors of the aforementioned companies.

Mr. FUNG obtained his bachelor's degree in accounting from The Hong Kong Polytechnic University (formerly known as Hong Kong Polytechnic) in Hong Kong in October 1992. Mr. FUNG has been a fellow of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants since October 2001 and September 2005, respectively.

Dr. GONG Yan (龔焱) ("Dr. GONG")

Dr. GONG Yan, aged 52, is proposed to be appointed as an independent non-executive Director in June 2026. Dr. GONG will be primarily responsible for providing independent opinion and judgment to the Board.

Dr. GONG served as an assistant professor at the University of California, Irvine (加州大學爾灣分校) from July 2007 to June 2013, specializing in corporate strategic transformation, lean entrepreneurship and business model innovation. He has been working at the China Europe International Business School (中歐國際工商學院) since July 2013, where he currently serves as a professor of management practice. From May 2016 to May 2023, he served as an independent director of Giant Network Group Co., Ltd. (巨人網絡集團股份有限公司) (Shenzhen Stock Exchange stock code: 002558). He has been an independent director of Gamehaus Holdings Inc.(家游控股有限公司) (Nasdaq Stock Exchange stock symbol: GMHS) since January 2025.

Dr. GONG obtained his bachelor's degree in engineering from Hunan University (湖南大學) in the PRC in July 1994, his master's degree in business administration from Zhejiang University (浙江大學) in the PRC in March 2001, and his doctor's degree from the University of Wisconsin-Madison in the United States in August 2007.

Dr. JIANG, Mr. FUNG and Dr. GONG have each confirmed that (i) they meet each of the independence factors set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) they have no past or present financial or other interests in the business of the Company or its subsidiaries, or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect their independence at the time of their appointment.

In considering the proposed independent non-executive Directors for the third session of the Board, the Nomination Committee has taken into account the independence confirmations of Dr. JIANG, Mr. FUNG and Dr. GONG, as well as their skills, background, knowledge and experience. In particular, Dr. JIANG has extensive experience in the investment and asset valuation industry, Mr. FUNG has extensive experience in accounting, advisory services, investor relations and financial management, and Dr. GONG has extensive experience in corporate strategic transformation, lean entrepreneurship, and business model innovation. Their diverse educational backgrounds, professional expertise and practice enable them to provide relevant and valuable insights and contribute to the diversity of the Board.

Further Details Regarding the Proposed Re-Election and Election of Directors

The proposed appointment of the Candidate Directors is subject to the approval of the Shareholders at the AGM. The Company proposes to enter into a service contract with each of the Candidate Directors for a term of three years commencing on the date of appointment approved by the AGM. The term of office of the Candidate Directors will be subject to the provisions of the Articles of Association, and shall be eligible for re-election upon the expiry of their term of office.

Upon the appointment of the Candidate Directors being approved by the Shareholders at the AGM, the re-elected Directors will continue to perform their existing duties, and the newly elected Directors will assume their corresponding responsibilities with effect from their appointments, while Dr. JIANG, Mr. FUNG and Dr. GONG, as proposed independent non-executive Directors, will be primarily responsible for providing independent advice to the Board.

The remuneration of the Directors is determined based on industry conditions as well as the scale and actual circumstances of the Company. Dr. ZHAO, Mr. MA, Mr. ZHANG, Mr. LU, Ms. NI and Ms. WAN will not receive any remuneration for serving as executive Directors. Dr. ZHAO, Mr. MA, Mr. ZHANG, Mr. LU, Ms. NI and Ms. WAN currently hold other positions in the Company and will receive remuneration in respect of such other positions they hold in the Company. The remuneration of Dr. ZHAO, Mr. MA, Mr. ZHANG, Mr. LU, Ms. NI and Ms. WAN will be determined in accordance with the relevant remuneration and assessment policies of the Company based on the specific positions they hold in the Company. The relevant remuneration will be determined with reference to their duties, experience, positions, individual performance, the Group's results, and prevailing market levels. The Company will disclose the specific details of the annual remuneration in its annual report to be published each year. Dr. JIANG, Mr. FUNG and Dr. GONG, as independent non-executive Directors, will be entitled to receive an annual remuneration of RMB180,000 (before tax), HK$240,000 (before tax) and RMB180,000 (before tax), respectively.

As at the date of this announcement, the total number of issued shares of the Company is 563,779,000 shares, comprising 363,186,467 domestic shares and 200,592,533 H shares.

As at the date of this announcement, under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"), Dr. ZHAO has a long position in an aggregate of 145,840,149 shares and underlying shares, representing approximately 25.87% of the total number of issued shares of the Company, comprising: (i) 93,042,388 domestic shares; (ii) 45,503,584 domestic shares held through corporations controlled by him; (iii) 6,077,677 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026; and (iv) 1,216,500 H shares held through corporations controlled by him. Among such shares, Dr. ZHAO has an interest in an aggregate of 138,545,972 domestic shares, representing approximately 38.15% of the total number of issued domestic shares of the Company; and has an interest in an aggregate of 7,294,177 H shares and underlying H shares, representing approximately 3.64% of the total number of issued H shares of the Company.

As at the date of this announcement, under Part XV of the SFO, Mr. ZHANG has a long position in an aggregate of 20,347,893 shares and underlying shares, representing approximately 3.61% of the total number of issued shares of the Company, comprising: (i) 20,312,190 domestic shares held through corporations controlled by him; and (ii) 35,703 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026. Among such shares, Mr. ZHANG has an interest in 20,312,190 domestic shares, representing approximately 5.59% of the total number of issued domestic shares of the Company; and has an interest in 35,703 underlying H shares, representing approximately 0.02% of the total number of issued H shares of the Company.

As at the date of this announcement, under Part XV of the SFO, Mr. MA has a long position in 593,680 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.11% of the total number of issued shares of the Company and approximately 0.30% of the total number of issued H shares of the Company.

As at the date of this announcement, under Part XV of the SFO, Mr. LU has a long position in 1,818,820 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.32% of the total number of issued shares of the Company and approximately 0.91% of the total number of issued H shares of the Company.

As at the date of this announcement, under Part XV of the SFO, Ms. NI has a long position in 1,388,772 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.25% of the total number of issued shares of the Company and approximately 0.69% of the total number of issued H shares of the Company.

As at the date of this announcement, under Part XV of the SFO, Ms. WAN has a long position in an aggregate of 41,496,851 shares and underlying shares, representing approximately 7.36% of the total number of issued shares of the Company, comprising: (i) 39,657,056 domestic shares held through corporations controlled by her; and (ii) 1,839,795 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026. Among such shares, Ms. WAN has an interest in 39,657,056 domestic shares, representing approximately 10.92% of the total number of issued domestic shares of the Company; and has an interest in 1,839,795 underlying H shares, representing approximately 0.92% of the total number of issued H shares of the Company.

The underlying H shares under the 2026 H Share Award Scheme mentioned above are all underlying H shares relating to unvested awards that have not yet been vested. As at the date of this announcement, such awards have not yet been vested and are subject to the satisfaction of the relevant vesting conditions before they can be vested.

As at the date of this announcement, save as disclosed above, each Candidate Director (i) does not hold any position in any other member of the Group; (ii) does not have any relationship with any Director, Supervisor, senior management member, or substantial or controlling shareholder of the Company; (iii) has not held any directorship in any other listed public company in the past three years; and (iv) does not have or is not deemed to have any interest or short position in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in Part XV of the SFO).

As at the date of this announcement, save as disclosed above, the Board is not aware of any other matters relating to the appointment of the Candidate Directors that need to be brought to the attention of the Shareholders, nor is there any other information that is required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules.

The biographical details of each Candidate Supervisor are as follows:

Mr. WEN Gang (文綱) ("Mr. WEN")

Mr. WEN Gang, aged 48, has been a Shareholders' representative Supervisor since September 2020. He is primarily responsible for the supervision of the performance of our Directors and members of our senior management in performing their duties to our Company and performing other supervisory duties as a Supervisor.

Mr. WEN has more than 11 years of experience in investment. From June 2015 to October 2020, Mr. WEN was a supervisor of Beijing Kangfujiahe Medical Equipment Co., Ltd. (北京康福嘉和醫療器械有限公司).

Besides, since November 2013, Mr. WEN has also been a partner of Ningbo Free Trade Zone Kaifeng Venture Capital Management Co., Ltd. (寧波保税區凱風創業投資管理有限公司), an investment company, where he has been primarily responsible for managing investments in the biomedical sector. Besides, Mr. WEN is also currently a director of Beijing Kaifeng Jingde Management Consulting Co., Ltd. (北京凱風景德管理諮詢有限公司) (a business consultancy firm), Sinovation (Beijing) Medical Technology Co., Ltd. (華科精準(北京)醫療科技有限公司) (a company principally engaged in development of medical robotics and intelligent medical products), Neuracle Technology (Changzhou) Co., Ltd. (博睿康科技(常州)股份有限公司) (a company principally engaged in R&D, production, sales and technical service of brain computer interface and medical neuro-electrophysiological equipment), Hangzhou Bioeast BioTech Co., Ltd (杭州博岳生物技術有限公司) (a company principally engaged in provision of molecular diagnostic reagents and kits for medical science industries), Fang Cun Quan Xiang (Beijing) Technology Co., Ltd. (方寸泉香(北京)科技有限公司) (an internet medical service provider), InsureSmart (Shanghai) Intelligent Technology Co., Ltd. (因朔桔(上海)智能科技有限公司) (an artificial intelligence technology application service provider with a focus on the healthcare and insurance industries), YW MEMS (Suzhou) Co., Ltd. (蘇州原位芯片科技有限責任公司) (a company principally engaged in design and manufacturing of microelectromechanical systems chips), Shanghai Yinlu Information Technology Co., Ltd. (上海飲露信息科技有限公司) (a company principally engaged in provision of healthcare venture capital advisory services), Beijing Jingyilin International Hospital Management Co., Ltd. (北京菁醫林國際醫院管理有限公司) (a company principally engaged in provision of medical and healthcare services), Hangzhou Tiaoding Data Co., Ltd. (杭州調鼎數據有限公司) (a company principally engaged in providing intelligent information solutions for hospital health management and physical examination centers), Beijing Yaputuo Medical Technology Co., Ltd. (北京亞普拓醫療科技股份有限公司) (a company principally engaged in provision of private healthcare services), Red Cloud Bio Co., Ltd. (南京紅雲生物科技有限公司) (a small molecule drug discovery and development biotech company), Gege Medical Technology (Shanghai) Co., Ltd. (格格醫療科技(上海)有限公司) (a technology-based healthcare services provider) and Wuhan Tian Shi Wei Biotech Co., Ltd. (武漢天時維控股有限公司) (a manufacturer of soluble microcrystalline skin care products).

Mr. WEN obtained his bachelor's degree in clinical medicine and his master's degree in clinical medicine in July 2000 and July 2003, respectively, from Peking Union Medical College (北京協和醫學院) (formerly known as China Union Medical College (中國協和醫科大學)) in Beijing.

Mr. CAI Xin (蔡鑫) ("Mr. CAI")

Mr. CAI Xin, aged 45, is a Shareholders' representative Supervisor. He joined our Group as a deputy director of the image delivery center of commercial operations division of our Company in September 2017, and was the director of the same center between April 2018 and February 2024. He has been our vice president and the head of the image delivery center of commercial operations division since February 2024. Further, Mr. CAI has been our Supervisor since March 2024. As our Supervisor, he is primarily responsible for the supervision of the performance of our Directors and members of our senior management in performing their duties to our Company and performing other supervisory duties as a Supervisor.

Mr. CAI has more than 16 years of experience in the pharmaceutical industry. Prior to joining our Group, from December 2008 to October 2013, he was a research associate at Washington University in St. Louis in the United States. From October 2013 to May 2015, he was a project manager at Hangzhou Tigermed Consulting Co., Ltd (杭州泰格醫藥科技股份有限公司), a company listed on the Stock Exchange (stock code: 3347) and the Shenzhen Stock Exchange (stock code: 300347), where he was primarily responsible for project management.

From June 2015 to September 2017, Mr. CAI was a client operations manager at Parexel China Co., Ltd. (精鼎醫藥研究開發(上海)有限公司), a contract research organization, where he was primarily responsible for project management and customer support.

Mr. CAI obtained his bachelor's degree in computer science and technology from Wuhan University (武漢大學) in Hubei in June 2002. He further obtained his master's degree in biomedical engineering from Huazhong University of Science and Technology (華中科技大學) in Hubei and his master's degree in business administration from Fudan University (復旦大學) in Shanghai in December 2008 and June 2024, respectively.

FURTHER DETAILS REGARDING THE PROPOSED RE-ELECTION OF SUPERVISORS

The proposed appointment of the Candidate Supervisors is subject to the approval of the Shareholders at the AGM. The Company proposes to enter into a service contract with each of the Candidate Supervisors for a term of three years commencing on the date of appointment approved by the AGM. The term of office of the Candidate Supervisors shall be the same as stipulated in the Articles of Association, and upon expiry of the term, they shall be eligible for re-election.

Upon the appointment of the Candidate Supervisors being approved by the Shareholders at the AGM, the Candidate Supervisors who are re-elected will continue to perform their previous duties and functions. Mr. CAI Xin will not receive any remuneration for serving as a Shareholder representative Supervisor and will receive remuneration in accordance with the Company's relevant remuneration and assessment system, based on his other positions held in the Company; Mr. WEN Gang will not receive any remuneration for serving as a Shareholder representative Supervisor.

As at the date of this announcement, save as disclosed above, each Candidate Supervisor (i) does not hold any position in any other member of the Group; (ii) does not have any relationship with any Director, Supervisor, senior management member, or substantial or controlling shareholder of the Company; (iii) has not held any directorship in any other listed public company in the past three years; and (iv) does not have or is not deemed to have any interest or short position in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in Part XV of the SFO).

As at the date of this announcement, save as disclosed above, the Board is not aware of any other matters relating to the appointment of the Candidate Supervisors that need to be brought to the attention of the Shareholders, nor is there any other information that is required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules.